Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

NCT00989404 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza A Virus, H1N1 Subtype

Interventions

DRUG: Zanamivir
DRUG: Zanamivir
DRUG: Zanamivir

Sponsor

GlaxoSmithKline